NeuroDerm
Latest round
- Series A
Last raised
- Jul 2007
Total raised
- $2.5M
Investors
- 1
About NeuroDerm
NeuroDerm Ltd.Founded in 2003 and headquartered in Rehovot, Israel, NeuroDerm specializes in drug-device combination solutions for Parkinson's disease.00 mn, effectively marking a pivotal moment in its business strategy and operations.NeuroDerm specializes in developing innovative drug-device combination solutions, primarily targeting central nervous system disorders, with a particular emphasis on Parkinson's disease. Their flagship product, ND0612, is a proprietary formulation of levodopa/carbidopa designed for continuous subcutaneous delivery, which aims to address motor fluctuations in Parkinson's patients. This user-friendly system includes a compact and portable infusion pump that allows for self-administration, thereby enhancing patient autonomy. NeuroDerm's products are geared toward improving the quality of life for patients and their families by reducing the disease burden associated with Parkinson's.S.NeuroDerm's revenue is primarily derived from the commercialization of its flagship product, ND0612, once it receives necessary approvals and enters the market. The company has established a framework for transactions that includes partnerships with pharmaceutical firms, healthcare providers, and potentially direct sales to consumers. These transactions are expected to be structured as B2B engagements, where healthcare institutions and pharmacies facilitate access to NeuroDerm's therapies for patients. The pricing plans for ND0612 are anticipated to reflect its status as a next-generation treatment for Parkinson's disease, focusing on the value it provides in managing symptoms and improving patient outcomes.NeuroDerm aims to expand its product line and market presence significantly.00 mn, will be pivotal in advancing their late-stage development of ND0612 and supporting marketing efforts. The company plans to introduce ND0612 into new markets in North America and Europe, pending regulatory approval, which is crucial for their growth strategy. NeuroDerm is focused on enhancing its drug-device combinations to further address unmet needs in Parkinson’s disease management.
Who invested in NeuroDerm
1 investor across 1 round
See all investors in NeuroDerm
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 23, 2007
Amount
$2.5M
Investors
Questions about NeuroDerm
Who invested in NeuroDerm?
NeuroDerm has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NeuroDerm raised?
NeuroDerm has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did NeuroDerm last raise money?
NeuroDerm's most recent round on record is a Series A, in Jul 2007.
What does NeuroDerm do?
NeuroDerm is a pharmaceuticals company.
Where is NeuroDerm headquartered?
NeuroDerm is headquartered in Rehovot, Israel.
Which VCs invest in companies like NeuroDerm?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at NeuroDerm's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like NeuroDerm? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.